Worth reading
72In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
52.6
Standalone sales year-on-year growth rate (%)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationFirst quarter of the fiscal year ending June 202710 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥3,621 million consolidated
Operating profit¥925 million consolidated
Ordinary income¥844 million consolidated
Net income¥576 million quarterly net income attributable to owners of the parent, consolidated
Gross Profit Margin62.5%
Operating profit margin25.6% (consolidated)
Results for the three months of the current quarterStandalone: sales of ¥3,613 million, operating profit of ¥989 million, ordinary profit of ¥908 million, and net income of ¥620 million. Consolidated: sales of ¥3,621 million, operating profit of ¥925 million, ordinary profit of ¥844 million, and quarterly net income attributable to owners of the parent of ¥576 million.
Full-year earnings forecast
Net Sales
16,730 Millions of yen
Operating profit
4,374 Millions of yen
Ordinary income
4,026 Millions of yen
Net income for the current fiscal year
2,965 Millions of yen
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales21.6%
Operating profit21.1%
Ordinary income21.0%
Profit for the period19.4%
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Change in salesCOVID-19 single-product volume factor: -¥228 million; combo volume factor: ¥745 million; influenza volume factor: ¥509 million; selling-price factor across all products: ¥76 million; other: ¥141 million
Change in operating incomeCOVID-19 sales change: -¥198 million; combo sales change: ¥502 million; influenza sales change: ¥309 million; cost fluctuation across all products: -¥160 million; other: -¥10 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
- Some expansion in market share following the launch of ImmunoAce SARS-CoV-2/Flu II
- A slight decline in selling prices based on historical trends
- Higher depreciation expenses associated with the full-scale operation of the Mt. Fuji Mishima Plant
- Rising Labor Costs
New initiatives
- ImmunoAce SARS-CoV-2/Flu II was launched on 17 September 2026, promoting expansion of the market share of combo test kits.
- Expanding sales of medical AI-related products through クレアボ・テクノロジーズ, while preparing to launch new products focused on the cardiovascular field and strengthening the business platform
- Raise the floor for the progressive dividend to ¥29 per share from the fiscal year ending June 2027 through the fiscal year ending June 2031
Key KPIsA metric the company considers important as a management benchmark.
- Influenza test kit market share46 %
- Standalone COVID-19 test kit market share45 %
- Market share of COVID-19/influenza combo test kits19 %
- Adenovirus test kit market share34 %
- Researchers on staff55 people
Unit price and quantity metricsThese figures show sales broken down by price and volume.
The company discloses sales-volume and selling-price factors by major product. Selling prices have remained within the range assumed at the beginning of the fiscal year, and a slight decline is expected.Market Size / Share
In the domestic antigen test kit market for medical institutions in the first quarter of the fiscal year ending June 2027, COVID-19 single-product kits contracted by slightly over 60% year on year, influenza kits expanded by slightly under 60%, and combo kits were broadly unchanged from the same period of the previous year. Market shares were 46% for influenza, 34% for adenovirus, 45% for COVID-19, and 19% for combo kits.Number of stores and locations
Head office and Kamishima Plant, Mt. Fuji Mishima Plant, Shimizucho Office and R&D Center, and Tokyo Office. The number of openings and closures during the period was Not disclosed.Number of employees
Number of Employees421 people as of 30 September 2026
Capital expenditures
¥1,699 million planned capital investment for the fiscal year ending June 2027
Annual Dividend
¥29 per share
Interim14.5
End of period14.5
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | First quarter of the fiscal year ending June 2027 |
| Net Sales | ¥3,621 million (consolidated) |
| Operating profit | ¥925 million (consolidated) |
| Ordinary income | ¥844 million (consolidated) |
| Net income | ¥576 million (quarterly net income attributable to owners of the parent, consolidated) |
| Gross Profit Margin | 62.5% |
| Operating profit margin | 25.6% (consolidated) |
| Results for the three months of the current quarter | Standalone: sales of ¥3,613 million, operating profit of ¥989 million, ordinary profit of ¥908 million, and net income of ¥620 million. Consolidated: sales of ¥3,621 million, operating profit of ¥925 million, ordinary profit of ¥844 million, and quarterly net income attributable to owners of the parent of ¥576 million. |
| Full-year earnings forecast | Net Sales 16,730 Millions of yen / Operating profit 4,374 Millions of yen / Ordinary income 4,026 Millions of yen / Net income for the current fiscal year 2,965 Millions of yen |
| Progress against full-year forecast | Net Sales 21.6% / Operating profit 21.1% / Ordinary income 21.0% / Profit for the period 19.4% |
| Breakdown of Factors Affecting the Change | Change in sales COVID-19 single-product volume factor: -¥228 million; combo volume factor: ¥745 million; influenza volume factor: ¥509 million; selling-price factor across all products: ¥76 million; other: ¥141 million / Change in operating income COVID-19 sales change: -¥198 million; combo sales change: ¥502 million; influenza sales change: ¥309 million; cost fluctuation across all products: -¥160 million; other: -¥10 million |
| Key KPIs | Indicator name Influenza test kit market share / Value 46 % / Year on year against the same period last year Not disclosed, Indicator name Standalone COVID-19 test kit market share / Value 45 % / Year on year against the same period last year Not disclosed, Indicator name Market share of COVID-19/influenza combo test kits / Value 19 % / Year on year against the same period last year Not disclosed, Indicator name Adenovirus test kit market share / Value 34 % / Year on year against the same period last year Not disclosed, Indicator name Researchers on staff / Value 55 people / Year on year against the same period last year Not disclosed |
| Unit price and quantity metrics | The company discloses sales-volume and selling-price factors by major product. Selling prices have remained within the range assumed at the beginning of the fiscal year, and a slight decline is expected. |
| Number of stores and locations | Head office and Kamishima Plant, Mt. Fuji Mishima Plant, Shimizucho Office and R&D Center, and Tokyo Office. The number of openings and closures during the period was Not disclosed. |
| Number of employees | Number of Employees 421 people (as of 30 September 2026) / Change during the period Not disclosed / Hiring plan Not disclosed |
| Assumptions Underlying the Business Outlook | Some expansion in market share following the launch of ImmunoAce SARS-CoV-2/Flu II, A slight decline in selling prices based on historical trends, Higher depreciation expenses associated with the full-scale operation of the Mt. Fuji Mishima Plant, Rising Labor Costs |
| Annual Dividend | ¥29 per share |
| Capital expenditures | ¥1,699 million (planned capital investment for the fiscal year ending June 2027) |
| Market Size / Share | In the domestic antigen test kit market for medical institutions in the first quarter of the fiscal year ending June 2027, COVID-19 single-product kits contracted by slightly over 60% year on year, influenza kits expanded by slightly under 60%, and combo kits were broadly unchanged from the same period of the previous year. Market shares were 46% for influenza, 34% for adenovirus, 45% for COVID-19, and 19% for combo kits. |
| New initiatives | ImmunoAce SARS-CoV-2/Flu II was launched on 17 September 2026, promoting expansion of the market share of combo test kits., Expanding sales of medical AI-related products through クレアボ・テクノロジーズ, while preparing to launch new products focused on the cardiovascular field and strengthening the business platform, Raise the floor for the progressive dividend to ¥29 per share from the fiscal year ending June 2027 through the fiscal year ending June 2031 |
Items this document does not state (10)
Selling, general and administrative expensesSelf-assessment against the planSegment resultsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsPayout ratioAcquisition of treasury sharesOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The impact of market inventory adjustments that had occurred in the same period of the previous year had dissipated, the influenza season began earlier than usual, and ImmunoAce SARS-CoV-2/Flu II, launched on 17 September 2026, contributed to results.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.